Instituto Valenciano de Infertilidad

Instituto Valenciano de Infertilidad (IVI) is a world-leading healthcare and research institution specializing in assisted reproduction and human genetics. Founded in 1990 in Valencia, Spain, it has grown into a global powerhouse through its merger with Reproductive Medicine Associates of New Jersey to form IVI-RMA Global. The company provides a full spectrum of fertility services, including in vitro fertilization, egg donation, and advanced genetic screening. IVI is distinguished by its significant commitment to research and development, particularly through the IVI Foundation, which explores innovative therapies like ovarian rejuvenation and non-invasive embryo testing. In 2022, the private equity firm KKR acquired a majority stake in the company, valuing it at approximately $3 billion. With a presence in over nine countries, IVI continues to set international standards for clinical excellence and scientific advancement in reproductive medicine.